Clinical Trial: Burns

Next Study

Full Name

Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries

Description

MediWound Ltd, the sponsor of this investigational treatment, has developed NexoBrid®. This
drug contains enzymes (substances to assist in breaking down burn-damaged skin and tissues,
without damaging healthy tissue). Treatment with NexoBrid® lasts for 4 hours. There is an additional 2 hour wound cleansing before and after the application of the investigational treatment medication. The total period of time in the investigational treatment protocol will be approximately 13.5 months for follow-up appointments, depending on the time it takes for the burn wounds to heal.

Purpose

To allow treatment to remove damaged skin and tissue without surgery and gather information on the investigational treatment, NexoBrid®. NexoBrid® will be applied to help remove damaged skin and tissue.

Eligibility

Inclusion Criteria

Inclusion Criteria-including but may not be limited to:

Participants hospitalized within 84 hours from injury due to deep burns (2nd degree deep and/or 3rd degree burns) caused by fire/flame, scalds or contact

To Participate

Please contact the Network Office of Research and Innovation at 610-402-9543.

For additional information

https://clinicaltrials.gov/ct2/show/NCT04040660?cond=NCT04040660&draw=2&rank=1

Doctor(s) Running This Study